No recent analyst price targets found for RVVTF.
Latest News for RVVTF
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RVVTF.
Senate Trading
No Senate trades found for RVVTF.
U.S. House Trading
No House trades found for RVVTF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.